EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Current progress of CDC20 in cancer development and targeting CDC20 for cancer therapy

Yingtong Chen iD, Shuang Gao iD, Ping Yang iD, Shuozi Liu iD, Weilong Zhang iD, Jing Wang iD, Hongmei Jing iD

Carcinogenesis · 2026

DOI: 10.1093/carcin/bgag021 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Carcinogenesis, 2026. Verfasst von Yingtong Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, 49 Huayuan North Road, Haidian District, Beijing 100191, China. Hauptthemen laut MEDLINE: Cdc20 Proteins, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 185 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Municipal Natural Science Foundation, Beijing Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell division cycle 20 homolog (CDC20), a critical substrate-recruiting subunit of the anaphase-promoting complex/cyclosome (APC/C), binds to APC/C to form the active APC/C-CDC20 complex, which regulates the degradation of key cell cycle substrates to ensure accurate and timely mitotic progression. Accumulating evidence demonstrates that CDC20 functions as an oncogenic factor, with its overexpression observed in various malignancies. Its dysregulation is closely associated with tumor initiation, progression, drug resistance, and poor clinical outcomes, underscoring its potential as a therapeutic target in anti-cancer strategies. In this review, we describe the biological functions of CDC20 in cancers, discuss its role and underlying mechanisms in solid tumors and hematological malignancies, and elucidate currently reported CDC20-targeted inhibitors along with their clinical benefits and challenges. By emphasizing the oncogenic significance of CDC20, we propose that the development of specific, safe, and potent CDC20 inhibitors could provide a promising therapeutic approach for cancer patients exhibiting CDC20 overexpression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cdc20 ProteinsNeoplasmsAntineoplastic AgentsHumansAnimalsMolecular Targeted TherapyAnaphase-Promoting Complex-Cyclosome

Stichwörter der Autor:innen

CDC20cancerinhibitorsmitosistherapy

Substanzen

Cdc20 ProteinsCDC20 protein, humanAntineoplastic AgentsAnaphase-Promoting Complex-Cyclosome

Autor:innen und Institutionen

  • Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, 49 Huayuan North Road, Haidian District, Beijing 100191, China.

ORCID-Profile: Yingtong Chen, Shuang Gao, Ping Yang, Shuozi Liu, Weilong Zhang, Jing Wang, Hongmei Jing

Förderung

  • National Natural Science Foundation of China
  • Beijing Municipal Natural Science Foundation
  • Beijing Municipal Health Commission

Zitieren

APA

Chen, Y., Gao, S., Yang, P., Liu, S., Zhang, W., Wang, J., & Jing, H. (2026). Current progress of CDC20 in cancer development and targeting CDC20 for cancer therapy. Carcinogenesis. https://doi.org/10.1093/carcin/bgag021

Vancouver

Chen Y, Gao S, Yang P, Liu S, Zhang W, Wang J, et al. Current progress of CDC20 in cancer development and targeting CDC20 for cancer therapy. Carcinogenesis. 2026. doi:10.1093/carcin/bgag021

BibTeX
@article{Chen2026,
  author = {Chen, Yingtong and Gao, Shuang and Yang, Ping and Liu, Shuozi and Zhang, Weilong and Wang, Jing and Jing, Hongmei},
  title = {Current progress of CDC20 in cancer development and targeting CDC20 for cancer therapy},
  journal = {Carcinogenesis},
  year = {2026},
  doi = {10.1093/carcin/bgag021}
}
Kostenlos starten →